122 related articles for article (PubMed ID: 7849302)
1. Absence of breast cancer cells in a single-day peripheral blood progenitor cell collection after priming with cyclophosphamide and granulocyte-macrophage colony-stimulating factor.
Passos-Coelho JL; Ross AA; Moss TJ; Davis JM; Huelskamp AM; Noga SJ; Davidson NE; Kennedy MJ
Blood; 1995 Feb; 85(4):1138-43. PubMed ID: 7849302
[TBL] [Abstract][Full Text] [Related]
2. Similar breast cancer cell contamination of single-day peripheral-blood progenitor-cell collections obtained after priming with hematopoietic growth factor alone or after cyclophosphamide followed by growth factor.
Passos-Coelho JL; Ross AA; Kahn DJ; Moss TJ; Davis JM; Huelskamp AM; Noga SJ; Davidson NE; Kennedy MJ
J Clin Oncol; 1996 Sep; 14(9):2569-75. PubMed ID: 8823337
[TBL] [Abstract][Full Text] [Related]
3. Predictive factors for peripheral-blood progenitor-cell collections using a single large-volume leukapheresis after cyclophosphamide and granulocyte-macrophage colony-stimulating factor mobilization.
Passos-Coelho JL; Braine HG; Davis JM; Huelskamp AM; Schepers KG; Ohly K; Clarke B; Wright SK; Noga SJ; Davidson NE
J Clin Oncol; 1995 Mar; 13(3):705-14. PubMed ID: 7533827
[TBL] [Abstract][Full Text] [Related]
4. Comparative effects of granulocyte-macrophage colony-stimulating factor (GM-CSF) and granulocyte colony-stimulating factor (G-CSF) on priming peripheral blood progenitor cells for use with autologous bone marrow after high-dose chemotherapy.
Peters WP; Rosner G; Ross M; Vredenburgh J; Meisenberg B; Gilbert C; Kurtzberg J
Blood; 1993 Apr; 81(7):1709-19. PubMed ID: 7681699
[TBL] [Abstract][Full Text] [Related]
5. Harvest quality and factors affecting collection and engraftment of CD34+ cells in patients with breast cancer scheduled for high-dose chemotherapy and peripheral blood progenitor cell support.
Papadopoulos KP; Ayello J; Tugulea S; Heitjan DF; Williams C; Reiss RF; Vahdat LT; Suciu-Foca N; Antman KH; Hesdorffer CS
J Hematother; 1997 Feb; 6(1):61-8. PubMed ID: 9112219
[TBL] [Abstract][Full Text] [Related]
6. Factors affecting the mobilization of primitive and committed hematopoietic progenitors into the peripheral blood of cancer patients.
Schneider JG; Crown JP; Wasserheit C; Kritz A; Wong G; Reich L; Norton L; Moore MA
Bone Marrow Transplant; 1994 Dec; 14(6):877-84. PubMed ID: 7536069
[TBL] [Abstract][Full Text] [Related]
7. Autologous progenitor cell transplantation: prior exposure to stem cell-toxic drugs determines yield and engraftment of peripheral blood progenitor cell but not of bone marrow grafts.
Dreger P; Klöss M; Petersen B; Haferlach T; Löffler H; Loeffler M; Schmitz N
Blood; 1995 Nov; 86(10):3970-8. PubMed ID: 7579368
[TBL] [Abstract][Full Text] [Related]
8. Bone marrow micrometastases in chemotherapy-responsive advanced breast cancer: effect of ex vivo purging with 4-hydroperoxycyclophosphamide.
Passos-Coelho J; Ross AA; Davis JM; Huelskamp AM; Clarke B; Noga SJ; Davidson NE; Kennedy MJ
Cancer Res; 1994 May; 54(9):2366-71. PubMed ID: 8162582
[TBL] [Abstract][Full Text] [Related]
9. The use of G-CSF or GM-CSF mobilized peripheral blood progenitor cells (PBPC) alone or to augment marrow as hematologic support of single or multiple cycle high-dose chemotherapy.
Elias AD; Ayash L; Tepler I; Wheeler C; Schwartz G; Mazanet R; Schnipper L; Frei E; Antman K
J Hematother; 1993; 2(3):377-82. PubMed ID: 7522891
[TBL] [Abstract][Full Text] [Related]
10. Enhanced levels and enhanced clonogenic capacity of blood progenitor cells following administration of stem cell factor plus granulocyte colony-stimulating factor to humans.
Begley CG; Basser R; Mansfield R; Thomson B; Parker WR; Layton J; To B; Cebon J; Sheridan WP; Fox RM; Green MD
Blood; 1997 Nov; 90(9):3378-89. PubMed ID: 9345020
[TBL] [Abstract][Full Text] [Related]
11. Peripheral blood progenitor cell (PBPC) counts during steady-state hematopoiesis allow to estimate the yield of mobilized PBPC after filgrastim (R-metHuG-CSF)-supported cytotoxic chemotherapy.
Fruehauf S; Haas R; Conradt C; Murea S; Witt B; Möhle R; Hunstein W
Blood; 1995 May; 85(9):2619-26. PubMed ID: 7537123
[TBL] [Abstract][Full Text] [Related]
12. Incidence of tumor-cell contamination in leukapheresis products of breast cancer patients mobilized with stem cell factor and granulocyte colony-stimulating factor (G-CSF) or with G-CSF alone.
Franklin WA; Glaspy J; Pflaumer SM; Jones RB; Hami L; Martinez C; Murphy JR; Shpall EJ
Blood; 1999 Jul; 94(1):340-7. PubMed ID: 10381531
[TBL] [Abstract][Full Text] [Related]
13. Blood-derived autografts collected during granulocyte colony-stimulating factor-enhanced recovery are enriched with early Thy-1+ hematopoietic progenitor cells.
Haas R; Möhle R; Pförsich M; Fruehauf S; Witt B; Goldschmidt H; Hunstein W
Blood; 1995 Apr; 85(7):1936-43. PubMed ID: 7535595
[TBL] [Abstract][Full Text] [Related]
14. Mobilization of peripheral blood progenitor cells by chemotherapy and granulocyte-macrophage colony-stimulating factor for hematologic support after high-dose intensification for breast cancer.
Elias AD; Ayash L; Anderson KC; Hunt M; Wheeler C; Schwartz G; Tepler I; Mazanet R; Lynch C; Pap S
Blood; 1992 Jun; 79(11):3036-44. PubMed ID: 1350229
[TBL] [Abstract][Full Text] [Related]
15. Mobilization of peripheral blood progenitor cells (PBPC) through a combination of chemotherapy and G-CSF in breast cancer patients and a possibility of unprocessed whole blood collection.
Vanásek J; Filip S; Medková V; Bláha M; Mericka P; Volenec K
Bone Marrow Transplant; 1998 Jan; 21(2):123-6. PubMed ID: 9489627
[TBL] [Abstract][Full Text] [Related]
16. Bone marrow versus peripheral blood progenitor cells CD34 selection in patients with non-Hodgkin's lymphomas: different levels of tumor cell reduction. Implications for autografting.
Lopez M; Lemoine FM; Firat H; Fouillard L; Laporte JP; Lesage S; Isnard F; Stachowiak J; Ferrer-Le Coeur F; Morel P; Najman A; Douay L; Gorin NC
Blood; 1997 Oct; 90(7):2830-8. PubMed ID: 9326252
[TBL] [Abstract][Full Text] [Related]
17. Biological properties of peripheral blood progenitor cells mobilized by cyclophosphamide and granulocyte colony-stimulating factor.
Scott MA; Apperley JF; Bloxham DM; Jestice HK; John S; Marcus RE; Gordon MY
Br J Haematol; 1997 May; 97(2):474-80. PubMed ID: 9163618
[TBL] [Abstract][Full Text] [Related]
18. Comparison of the content and subpopulations of CD3 and CD34 positive cells in bone marrow harvests and G-CSF-mobilized peripheral blood leukapheresis products from healthy adult donors.
Hassan HT; Stockschläder M; Schleimer B; Krüger W; Zander AR
Transpl Immunol; 1996 Dec; 4(4):319-23. PubMed ID: 8972563
[TBL] [Abstract][Full Text] [Related]
19. Flt3 ligand synergizes with granulocyte-macrophage colony-stimulating factor or granulocyte colony-stimulating factor to mobilize hematopoietic progenitor cells into the peripheral blood of mice.
Brasel K; McKenna HJ; Charrier K; Morrissey PJ; Williams DE; Lyman SD
Blood; 1997 Nov; 90(9):3781-8. PubMed ID: 9345066
[TBL] [Abstract][Full Text] [Related]
20. Very large amounts of peripheral blood progenitor cells eliminate severe thrombocytopenia after high-dose melphalan in advanced breast cancer patients.
Benedetti G; Patoia L; Giglietti A; Alessio M; Pelicci P; Grignani F
Bone Marrow Transplant; 1999 Nov; 24(9):971-9. PubMed ID: 10556956
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
